Cidara Therapeutics (CDTX) Stock Forecast & Price Target

Compare

773 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CDTX Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Cidara

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CDTX Stock 12 Month Forecast

Average Price Target

$72.86

▲(17.52% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $72.86 with a high forecast of $115.00 and a low forecast of $45.00. The average price target represents a 17.52% change from the last price of $62.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","116":"$116","35.75":"$35.8","62.5":"$62.5","89.25":"$89.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,35.75,62.5,89.25,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.9,66.9076923076923,70.91538461538461,74.92307692307692,78.93076923076923,82.93846153846154,86.94615384615385,90.95384615384614,94.96153846153845,98.96923076923076,102.97692307692307,106.98461538461538,110.99230769230769,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.9,63.66615384615385,64.43230769230769,65.19846153846154,65.96461538461539,66.73076923076923,67.49692307692308,68.26307692307692,69.02923076923076,69.79538461538462,70.56153846153846,71.3276923076923,72.09384615384616,{"y":72.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.9,61.52307692307692,60.146153846153844,58.76923076923077,57.39230769230769,56.01538461538461,54.63846153846154,53.261538461538464,51.88461538461539,50.50769230769231,49.13076923076923,47.753846153846155,46.37692307692308,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.89,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$115.00

Average Price Target$72.86

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dex Genotek

TR | OpenAI - 4o

$57→$66

Hold

6.45%

Upside

Reiterated

08/12/25

AI Generated ArticleAI Generated Article

Joseph Stringer

Needham

$54→$74

Buy

19.35%

Upside

Reiterated

08/08/25

Cidara Therapeutics (CDTX) Receives a Buy from Needham

Sara Nik

H.C. Wainwright

$53→$74

Buy

19.35%

Upside

Reiterated

08/08/25

Cidara Therapeutics price target raised to $74 from $53 at H.C. WainwrightCidara Therapeutics price target raised to $74 from $53 at H.C. Wainwright

Roy Buchanan

Citizens JMP

$59→$66

Buy

6.45%

Upside

Reiterated

08/08/25

Cidara Therapeutics price target raised to $66 from $59 at Citizens JMPCidara Therapeutics price target raised to $66 from $59 at Citizens JMP

Seamus Fernandez

Guggenheim

$69→$70

Buy

12.90%

Upside

Reiterated

08/07/25

Cidara Therapeutics price target raised to $70 from $69 at GuggenheimCidara Therapeutics price target raised to $70 from $69 at Guggenheim

Brian Abrahams

RBC Capital

$75→$115

Buy

85.48%

Upside

Reiterated

08/06/25

RBC Capital Sticks to Its Buy Rating for Cidara Therapeutics (CDTX)

Stephen Brozak

WBB Securities

$45

Buy

-27.42%

Downside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX), Hims & Hers Health (NYSE: HIMS) and Biomea Fusion (NASDAQ: BMEA)

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

06/10/25

Cidara Therapeutics (CDTX) Receives a Buy from Cantor Fitzgerald

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dex Genotek

TR | OpenAI - 4o

$57→$66

Hold

6.45%

Upside

Reiterated

08/12/25

AI Generated ArticleAI Generated Article

Joseph Stringer

Needham

$54→$74

Buy

19.35%

Upside

Reiterated

08/08/25

Cidara Therapeutics (CDTX) Receives a Buy from Needham

Sara Nik

H.C. Wainwright

$53→$74

Buy

19.35%

Upside

Reiterated

08/08/25

Cidara Therapeutics price target raised to $74 from $53 at H.C. WainwrightCidara Therapeutics price target raised to $74 from $53 at H.C. Wainwright

Roy Buchanan

Citizens JMP

$59→$66

Buy

6.45%

Upside

Reiterated

08/08/25

Cidara Therapeutics price target raised to $66 from $59 at Citizens JMPCidara Therapeutics price target raised to $66 from $59 at Citizens JMP

Seamus Fernandez

Guggenheim

$69→$70

Buy

12.90%

Upside

Reiterated

08/07/25

Cidara Therapeutics price target raised to $70 from $69 at GuggenheimCidara Therapeutics price target raised to $70 from $69 at Guggenheim

Brian Abrahams

RBC Capital

$75→$115

Buy

85.48%

Upside

Reiterated

08/06/25

RBC Capital Sticks to Its Buy Rating for Cidara Therapeutics (CDTX)

Stephen Brozak

WBB Securities

$45

Buy

-27.42%

Downside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX), Hims & Hers Health (NYSE: HIMS) and Biomea Fusion (NASDAQ: BMEA)

Eric Schmidt FCA

Cantor Fitzgerald

―

Buy

―

Reiterated

06/10/25

Cidara Therapeutics (CDTX) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cidara Therapeutics

1 Month

xxx

Success Rate

7/8 ratings generated profit

Average Return

+30.63%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 87.50% of your transactions generating a profit, with an average return of +30.63% per trade.

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+29.23%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +29.23% per trade.

1 Year

Stephen BrozakWBB Securities

Success Rate

5/8 ratings generated profit

Average Return

+44.11%

reiterated a buy rating 2 months ago

Copying Stephen Brozak's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +44.11% per trade.

2 Years

xxx

Success Rate

5/8 ratings generated profit

Average Return

+45.46%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +45.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CDTX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CDTX has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. CDTX average Analyst price target in the past 3 months is 72.86.

Each month's total comprises the sum of three months' worth of ratings.

CDTX Financial Forecast

CDTX Earnings Forecast

Next quarter’s earnings estimate for CDTX is -$1.64 with a range of -$3.49 to -$1.17. The previous quarter’s EPS was -$1.65. CDTX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.02% of the time in the same period. In the last calendar year CDTX has Outperformed its overall industry.

CDTX Sales Forecast

Next quarter’s sales forecast for CDTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CDTX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 50.90% of the time in the same period. In the last calendar year CDTX has Preformed in-line its overall industry.

CDTX Stock Forecast FAQ

What is CDTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Cidara Therapeutics Inc.’s 12-month average price target is 72.86.

What is CDTX’s upside potential, based on the analysts’ average price target?

Cidara Therapeutics Inc. has 17.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CDTX a Buy, Sell or Hold?

Cidara Therapeutics Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Cidara Therapeutics Inc.’s price target?

The average price target for Cidara Therapeutics Inc. is 72.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $115.00 ,the lowest forecast is $45.00. The average price target represents 17.52% Increase from the current price of $62.

What do analysts say about Cidara Therapeutics Inc.?

Cidara Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CDTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cidara Therapeutics (CDTX) Stock Forecast & Price Target

CDTX Analyst Ratings

CDTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cidara Therapeutics

CDTX Analyst Recommendation Trends

CDTX Financial Forecast

CDTX Earnings Forecast

CDTX Sales Forecast

CDTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts